News

Measuring levels of protein sLR11 in the blood could be useful in testing for pulmonary hypertension (PH) in people who have heart failure, according to a new study. The study, “Circulating sLR11 levels predict severity of pulmonary hypertension due to left heart disease,” was published in…

High blood levels of NT-proBNP — a validated and widely accepted prognostic marker of pulmonary hypertension (PH) — may serve as a biomarker to diagnose PH among people with chronic obstructive pulmonary disease (COPD) exacerbations, according to a study in China. However, no significant association was detected between…

The use of imaging to evaluate the right side of the heart could be useful for non-invasively diagnosing and monitoring pulmonary arterial hypertension (PAH) in people with connective tissue diseases, according to a new study. The study, “Evaluation of pulmonary arterial pressure in patients with connective…

Gene activity analysis of whole blood collected from people with pulmonary arterial hypertension (PAH) identified three patient subgroups associated with distinct clinical features and outcomes, a study concluded. These findings may provide molecular insights into the development of PAH, improve disease risk assessments, and potentially guide individual treatment strategies,…

Team PHenomenal Hope’s research fund, the PHenomenal Impact Fund for Global PH Research, will help finance pulmonary hypertension (PH) research for the fourth consecutive year. “Team PHenomenal Hope [Team PH] actively seeks ways to improve the quality of life for those with Pulmonary Hypertension by building community, providing…

Increased lung arterial obstruction is significantly associated with greater airflow obstruction in people with chronic thromboembolic pulmonary hypertension (CTEPH) and without a smoking history, a study shows. Notably, airflow obstruction, reflected by a reduced ability to exhale quickly, was lessened with reduced arterial obstruction and improved blood flow following…

The levels of Piezo1, an ion channel that senses membrane tension in cells, was found to be increased in the lung blood vessels of patients with idiopathic pulmonary arterial hypertension (PAH) and in animal models of pulmonary hypertension (PH), a study says. Research showed that these higher levels…

In addition to lowering blood pressure, treatments for pulmonary arterial hypertension (PAH) probably work at least in part by preventing physical changes in the architecture of the lung’s blood vessels that are associated with the progression of the disease, according to a study. “Our findings suggest that the beneficial…

People with pulmonary hypertension are at increased risk of developing cancer, especially lung and skin cancers, a new study indicates. The study, “Pulmonary hypertension is associated with an increased incidence of cancer diagnoses,” was published in the journal Pulmonary Circulation. Pulmonary hypertension (PH) refers to…

Tenax Therapeutics has completed a pharmacological assessment of TNX-201, the company’s new oral formulation of imatinib for pulmonary arterial hypertension (PAH), in healthy volunteers. The assessment included comparisons against Gleevec, another oral formulation of imatinib sold by Novartis that is approved to treat certain blood cancers, but was…

Pulmonary Hypertension News brought you the latest coverage of advances in treatment, clinical trials, and scientific research related to pulmonary hypertension (PH) throughout 2021. We look forward to continuing to report more news to patients, family members, and caregivers dealing with PH in the new year. Here are the…

Care at a specialty center is tied to a lower risk of hospitalization for people with heart failure with preserved ejection fraction (HFpEF) who have pulmonary hypertension, according to a new study. The study, “Improved Hospitalization Rates in a Specialty Center for Heart Failure with Preserved Ejection Fraction…